DUBLIN, Ireland and MELBOURNE, Australia, June 4, 2015 (GLOBE NEWSWIRE) Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced statistically significant top-line results from its proof-of-concept (POC) efficacy study of NV-02, an anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy in development for the control of pain associated with degenerative joint disease (DJD), including […]

DUBLIN, Ireland and MELBOURNE, Australia, May 8, 2015 (GLOBE NEWSWIRE) — Veterinary biologic therapy developer Nexvet Biopharma (Nasdaq:NVET) today announced its financial results for the three and nine month periods ended March 31, 2015. Link here. Corporate Highlights In February 2015, we closed our initial public offering of 4.0 million ordinary shares at a price to […]

By Renaissance Capital,  December 30, 2014 Link here. Nexvet, which is developing biologics for the treatment of pain and inflammation in cats and dogs, filed on Tuesday with the SEC to raise up to $60 million in an initial public offering. The Dublin, Ireland-based company, which was founded in 2010, plans to list on the NASDAQ […]

DUBLIN, Ireland; MELBOURNE, Australia –‐ December 3, 2014. Link here. Veterinary biologic therapy developer Nexvet Biopharma today announced the signing of a ten year collaboration and distribution agreement with Virbac (EPA:VIRP), one of the largest animal health dedicated companies in the world. Under the terms of the agreement, Virbac will distribute NV-01, Nexvet’s most advanced product, […]

15 September 2014. Posted in Pharma & Biopharma on 15 September, 2014. Nexvet Biopharma has added two former CSL (ASX:CSL) scientists to its veterinary biologics research team. CSL’s former director of preclinical cell biology, Dr Samantha Busfield, and former director of analytical biochemistry, Dr Dallas Hartman, have both joined Nexvet’s veterinary biologics research centre in Melbourne. The centre is designed […]